National Institute of Allergy and Infectious Diseases (NIAID)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).

2,006 total trials 155 currently recruiting 1642 completed early-phase tilt top decile by trial count

National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.

National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.

Top-decile sponsor footprint

National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 68/100

1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

2,006 total, page 20 of 41

COMPLETED Phase 1

Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine

NCT00473135
COMPLETED Phase 1

MVA Post-Event: Administration Timing and Boost Study

NCT00437021
COMPLETED Phase 1

Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults

NCT00428337
COMPLETED Phase 1

Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults

NCT00366782
COMPLETED Phase 1

Higher Dose Intradermal H5 Vaccine

NCT00439335
COMPLETED Phase 1

Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally

NCT00436046
COMPLETED Phase 1

Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus

NCT00458120
COMPLETED

Accuracy of Hemoglobin A1C to Predict Glycemia in HIV

NCT00433628
COMPLETED Phase 1

Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma

NCT00434421
COMPLETED Phase 2

Pioglitazone to Treat Fatty Liver in People With HIV Infection

NCT00441272
COMPLETED Phase 1

Open-Label Study of H5 Vaccine in Participants of Protocol 04-077

NCT00402649
COMPLETED

Clinical IGSP-CHOP Boston

NCT00428831
COMPLETED Phase 1

Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine

NCT00427167
COMPLETED Early Phase 1

Donor Stem Cell Transplantation for Congenital Immunodeficiencies

NCT00426517
COMPLETED Phase 3

Efficacy of Islet After Kidney Transplantation

NCT00468117
COMPLETED Phase 1

Adenovirus Vaccine for Malaria

NCT00371189
COMPLETED Phase 1

Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza

NCT00391768
COMPLETED Phase 1

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults

NCT00322946
COMPLETED

HIV Resistance and Treatment Strategies

NCT00581802
COMPLETED Phase 1

Safety Study of Avian Flu Vaccine

NCT00408109
COMPLETED Phase 2

Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults

NCT00376935
COMPLETED Phase 1

VivaGel™ in Healthy Young Women

NCT00331032
COMPLETED Phase 2

Strategies to Improve Islet Survival

NCT00464555
TERMINATED Phase 2

Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

NCT00346151
COMPLETED Phase 2

NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)

NCT00322465
COMPLETED Phase 4

Proteomic Profiling for Influenza

NCT00133588
COMPLETED

Inpatient Influenza Surveillance

NCT00419861
COMPLETED Phase 1

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

NCT00384787
TERMINATED Phase 1

Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)

NCT00396812
TERMINATED Phase 4

Th1 Response to Influenza: Aging and Vaccine Efficacy

NCT00396305
TERMINATED Phase 2

B-Lymphocyte Immunotherapy in Islet Transplantation

NCT00468442
TERMINATED Early Phase 1

Gene Therapy for Chronic Granulomatous Disease

NCT00394316
COMPLETED Phase 2

Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy

NCT00367458
COMPLETED Phase 2

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

NCT00339040
COMPLETED

ICATA Asthma Mechanistic Study

NCT00377390
COMPLETED Phase 3

Islet Transplantation in Type 1 Diabetes

NCT00434811
COMPLETED Phase 2

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

NCT00434850
COMPLETED Phase 1

Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)

NCT00380237
COMPLETED Phase 1

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults

NCT00375726
COMPLETED Phase 4

Proteomic Profiling for Influenza Vaccination - FluMist

NCT00385281
COMPLETED Phase 1

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

NCT00382980
COMPLETED Phase 4

Inner-City Anti-IgE Therapy for Asthma

NCT00377572
TERMINATED Phase 3

Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU

NCT00307099
COMPLETED Phase 1

Experimental Vaccine for Prevention of Ebola Virus Infection

NCT00374309
COMPLETED Phase 2

Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy

NCT00307164
TERMINATED Phase 1

B-19 Parvovirus Vaccine Study

NCT00379938
TERMINATED Phase 2

Development of Immune Globulin Treatment for Avian Flu

NCT00383071
COMPLETED

Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy

NCT00326482
TERMINATED

Investigation of Southern Tick-Associated Rash Illness (STARI)

NCT00358761
COMPLETED Phase 2

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study

NCT00288626
← Previous Page 20 of 41 Next →

Phase Distribution

PhaseTrial count
Phase 1 858
Phase 2 433
Phase 3 123
Phase 4 54

Therapeutic Areas

HIV Infections 195
Influenza 36
HIV 24
COVID-19 16
Malaria 14
Tuberculosis 13
Asthma 13
HIV Infection 12
Pneumonia, Pneumocystis Carinii 8
Atopic Dermatitis 7

What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline

155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).

Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).

Top condition: HIV Infections (195 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide

Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,0002,500 5%10%15%20% Total trials Recruiting share National Institute of Allergy and Infectious Diseases (NIAID)Massachusetts General HospitalMemorial Sloan Kettering Cancer CenterPfizerStanford UniversityAlumisAndrei IagaruBioXcel TherapeuticsCorporal Michael J. Crescenz VA Medical Center
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2,006 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page

2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.

  • 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.